Downregulation of RASSF6 is involved in neuroblastoma, melanoma, nasopharyngeal cancer and childhood acute lymphocytic leukemia, and its decreased expression level is also associated with poor survival of pancreatic ductal adenocarcinoma and gastric cancer [9–12, 14, 15]. Here, RASSF6 is linked to gastric cancer.